OBJECTIVES: Doravirine is a recently licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and safety profile compared with efavirenz and limited cross-resistance with rilpivirine and etravirine. In this in vitro study, cross-resistance to doravirine was analysed in a representative panel of NNRTI-resistant clones. METHODS: In vitro phenotypic susceptibility to doravirine was assessed in 10 clinically derived infectious clones with intermediate- to high-level resistance to rilpivirine, etravirine, efavirenz and nevirapine, and in NL4-3 site-directed mutants harbouring K103N, Y181C, M230L or K103N/Y181C NNRTI mutations. RESULTS: Although none of the infectious clones harboured any of the major doravirine resistance-associated mutations (RAMs) included in the IAS-USA reference list, doravirine fold change (FC) values were comparable to or higher than those calculated for other NNRTIs, particularly etravirine and rilpivirine. As expected, single NNRTI mutations K103N and Y181C did not impair doravirine susceptibility (FC 1.4 and 1.8, respectively), while reduced activity was observed with the single M230L or double K103N/Y181C mutations (FC 7.6 and 4.9, respectively). Median FC values increased significantly with increasing numbers of NNRTI RAMs (P = 0.005) and were >10 in 4/4 and 1/4 clones harbouring four and three NNRTI RAMs, respectively. FC values correlated well with predicted susceptibility as inferred by Stanford HIV Drug Resistance Database (HIVdb) and ANRS algorithms (both P < 0.001). CONCLUSIONS: Substantial cross-resistance to doravirine was detected in NNRTI-resistant viruses harbouring complex mutational patterns, even in the absence of major IAS-USA doravirine RAMs. Therefore, based on the simple IAS-USA reference list, doravirine resistance may be underestimated in viruses harbouring multiple NNRTI mutations.
OBJECTIVES: Doravirine is a recently licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and safety profile compared with efavirenz and limited cross-resistance with rilpivirine and etravirine. In this in vitro study, cross-resistance to doravirine was analysed in a representative panel of NNRTI-resistant clones. METHODS: In vitro phenotypic susceptibility to doravirine was assessed in 10 clinically derived infectious clones with intermediate- to high-level resistance to rilpivirine, etravirine, efavirenz and nevirapine, and in NL4-3 site-directed mutants harbouring K103N, Y181C, M230L or K103N/Y181C NNRTI mutations. RESULTS: Although none of the infectious clones harboured any of the major doravirine resistance-associated mutations (RAMs) included in the IAS-USA reference list, doravirine fold change (FC) values were comparable to or higher than those calculated for other NNRTIs, particularly etravirine and rilpivirine. As expected, single NNRTI mutations K103N and Y181C did not impair doravirine susceptibility (FC 1.4 and 1.8, respectively), while reduced activity was observed with the single M230L or double K103N/Y181C mutations (FC 7.6 and 4.9, respectively). Median FC values increased significantly with increasing numbers of NNRTI RAMs (P = 0.005) and were >10 in 4/4 and 1/4 clones harbouring four and three NNRTI RAMs, respectively. FC values correlated well with predicted susceptibility as inferred by Stanford HIV Drug Resistance Database (HIVdb) and ANRS algorithms (both P < 0.001). CONCLUSIONS: Substantial cross-resistance to doravirine was detected in NNRTI-resistant viruses harbouring complex mutational patterns, even in the absence of major IAS-USA doravirine RAMs. Therefore, based on the simple IAS-USA reference list, doravirine resistance may be underestimated in viruses harbouring multiple NNRTI mutations.
Authors: Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2019-09
Authors: Meizhen Feng; Deping Wang; Jay A Grobler; Daria J Hazuda; Michael D Miller; Ming-Tain Lai Journal: Antimicrob Agents Chemother Date: 2014-11-10 Impact factor: 5.191
Authors: Steven J Smith; Gary T Pauly; Aamir Akram; Kevin Melody; Zandrea Ambrose; Joel P Schneider; Stephen H Hughes Journal: J Acquir Immune Defic Syndr Date: 2016-08-15 Impact factor: 3.731
Authors: Meizhen Feng; Nancy A Sachs; Min Xu; Jay Grobler; Wade Blair; Daria J Hazuda; Michael D Miller; Ming-Tain Lai Journal: Antimicrob Agents Chemother Date: 2016-03-25 Impact factor: 5.191
Authors: Chloe Orkin; Kathleen E Squires; Jean-Michel Molina; Paul E Sax; Wing-Wai Wong; Otto Sussmann; Richard Kaplan; Lisa Lupinacci; Anthony Rodgers; Xia Xu; Gina Lin; Sushma Kumar; Peter Sklar; Bach-Yen Nguyen; George J Hanna; Carey Hwang; Elizabeth A Martin Journal: Clin Infect Dis Date: 2019-02-01 Impact factor: 9.079
Authors: Kim Steegen; Michelle Moorhouse; Annemarie Mj Wensing; Willem Df Venter; Lucia Hans Journal: J Int AIDS Soc Date: 2021-05 Impact factor: 5.396
Authors: Kate El Bouzidi; Rawlings P Datir; Vivian Kwaghe; Sunando Roy; Dan Frampton; Judith Breuer; Obinna Ogbanufe; Fati Murtala-Ibrahim; Man Charurat; Patrick Dakum; Caroline A Sabin; Nicaise Ndembi; Ravindra K Gupta Journal: J Antimicrob Chemother Date: 2022-02-02 Impact factor: 5.790
Authors: Ernest Asante-Appiah; Johnny Lai; Hong Wan; Dongmei Yang; Elizabeth Anne Martin; Peter Sklar; Daria Hazuda; Christos J Petropoulos; Charles Walworth; Jay A Grobler Journal: Antimicrob Agents Chemother Date: 2021-09-27 Impact factor: 5.191